Wouter Jukema, MD, PhD: PCSK9 Inhibitor Potential, Tolerability

(3:10)

Wouter Jukema, MD, PhD: ODYSSEY OUTCOMES in Post-Acute Coronary Syndrome

(3:7)

Promising results with the new lipid-modifying drugs. Prof. Dr. Wouter Jukema

(29:40)

ACSForum2020, 06. Pr. Jukema : An alternative cause of ACS

(21:1econd)

Conferencia de la Prof. J. Wouter Jukema en la XXXIV LECCIÓN MEMORIAL FERNÁNDEZ-CRUZ

(18:20)

Comprender la aterosclerosis en la era actual: Dr. J Wouter Lukema

(27:37)

Within the margins of emptiness | Nynke Rixt Jukema | TEDxFryslân

(15:23)

ESC TV at ACC.18 - Perspective - ODYSSEY Outcomes Trial

(4:39)

ACC.18 | ODYSSEY Outcomes

(5:33)

The Truth About Statins: Are They Safe For Your Cholesterol?

(11:57)

CardioEgypt 2024 - Minia Hall - Day 2 - Session 2 - Hypertension Drug Therapy is There Anything New

(1:5:11)

Repatha

(19:22)

KOLESTEROL İLAÇLARI İŞE YARIYOR MU, YAN TESİRLERİ, KİMLER ALMALI?

(20:3)

DON'T Exercise At This Time If You Want to Live Longer

(6:39)

Does Repatha Cause Muscle Pain

(8:37)

The SCORE2 and SCORE2 Op risk algorithms to estimate ASCVD risk

(45:4)

Amla – The Definitive Guide to the World’s Most Powerful Antioxidant

(11:30)

ACC Cardiology Hour at ACC.18 with Valentin Fuster, MD, PhD, MACC

(1:9:7)

Stanford Doctor on Preventing Heart Attacks in Those with Heart Disease

(1:3:58)

ODYSSEY OUTCOMES | ACC.19

(3:41)

ESC TV at ACC.18 - Results from the ODYSSEY Outcomes Trial

(3:26)

PCSK9 Inhibitors: Cost Concerns and Access

(8:6)

Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.

(2:41)

ACC 2018: Alirocumab In Patients After Acute Coronary Syndrome

(7:20)

Full Interview with Dr. Wouter Rietsema

(20:49)

PCSK9 inhibitors, rivaroxaban and a diabetes drug are major milestones in PAD treatment

(4:14)

Amgen - Hot or Not

(3:41)

ESC 23: LIBerate-HeFH: Novel PCSK9-Inhibitor in Heterozygous Familial Hypercholesterolemia

(4:17)

Hepatic Triglyceride Content Is Associated with Aortic Stiffness

(14:40)